Seegene Stock Net Income
| 096530 Stock | KRW 23,050 250.00 1.10% |
Seegene fundamentals help investors to digest information that contributes to Seegene's financial success or failures. It also enables traders to predict the movement of Seegene Stock. The fundamental analysis module provides a way to measure Seegene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Seegene stock.
Seegene |
Seegene Company Net Income Analysis
Seegene's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Seegene Net Income | 536.56 B |
Most of Seegene's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Seegene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Seegene reported net income of 536.56 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net income for all Republic of Korea stocks is notably lower than that of the firm.
Did you try this?
Run Commodity Channel Now
Commodity ChannelUse Commodity Channel Index to analyze current equity momentum |
| All Next | Launch Module |
Seegene Fundamentals
| Return On Equity | 0.32 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.30 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 3.51 T | |||
| Shares Outstanding | 25.99 M | |||
| Shares Owned By Insiders | 30.90 % | |||
| Shares Owned By Institutions | 9.23 % | |||
| Price To Earning | 140.12 X | |||
| Price To Sales | 0.65 X | |||
| Revenue | 1.37 T | |||
| Gross Profit | 1 T | |||
| EBITDA | 415.89 B | |||
| Net Income | 536.56 B | |||
| Cash And Equivalents | 432.13 B | |||
| Total Debt | 102.81 B | |||
| Debt To Equity | 8.90 % | |||
| Current Ratio | 4.91 X | |||
| Cash Flow From Operations | 334.02 B | |||
| Target Price | 52050.0 | |||
| Number Of Employees | 1.01 K | |||
| Beta | -0.97 | |||
| Market Capitalization | 700.48 B | |||
| Total Asset | 1.49 T | |||
| Retained Earnings | 46.11 B | |||
| Working Capital | 139.97 B | |||
| Current Asset | 151.8 B | |||
| Current Liabilities | 11.83 B | |||
| Z Score | 3.6 | |||
| Annual Yield | 0 % | |||
| Net Asset | 1.49 T |
About Seegene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Seegene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Seegene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Seegene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in Seegene Stock
Seegene financial ratios help investors to determine whether Seegene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Seegene with respect to the benefits of owning Seegene security.